Format

Send to

Choose Destination
Pain Manag. 2017 Jul;7(4):255-267. doi: 10.2217/pmt-2016-0067. Epub 2017 Apr 18.

Transdermal oxycodone patch for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled trial.

Author information

1
Phosphagenics Limited, 11 Duerdin Street, Clayton VIC 3168, Australia.
2
Health Writers S.L., Velazquez, 59 28001 Madrid, Spain.
3
MJC Pain Management Research Centre, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.

Abstract

AIM:

To evaluate the efficacy, systemic exposure, safety and tolerability of a transdermal oxycodone patch containing tocopheryl phosphate mixture (TPM) in patients with postherpetic neuralgia (PHN).

PATIENTS & METHODS:

The study was a Phase IIa, multicenter, randomized, double-blind, vehicle-controlled crossover study.

RESULTS:

While the TPM/oxycodone patch did not significantly improve 'average' Numeric Pain Rating Scale scores versus vehicle patch, patients reporting high levels of paresthesia (n = 9) showed a trend toward improved pain reduction. The TPM/oxycodone patch resulted in a low systemic exposure to oxycodone and was well tolerated.

CONCLUSION:

The TPM/oxycodone patch delivered oxycodone to the site of perceived pain in subjects suffering from PHN, but did not provide analgesia for the broad PHN indication.

KEYWORDS:

oxycodone; postherpetic neuralgia; transdermal patch

PMID:
28415907
DOI:
10.2217/pmt-2016-0067
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center